Kyverna Therapeutics Reports 2024 Financial Results and Business Update on Clinical Trials Kyverna Therapeutics shares insights on its financial performance for 2024 and updates on the clinical path for key autoimmune therapies targeting stiff person syndrome and myasthenia gravis.

Kyverna Therapeutics Reports 2024 Financial Results and Business Update on Clinical Trials #USA #Emeryville #Kyverna #KYV-101 #Autoimmune

Kyverna Therapeutics Investors Urged to Act on Class Action Lawsuit Before February 2025 Deadline Investors in Kyverna Therapeutics, Inc. are being reminded of a class action lawsuit deadline. The Gross Law Firm provides essential details for shareholders.

Kyverna Therapeutics Investors Urged to Act on Class Action Lawsuit Before February 2025 Deadline #United_States #New_York #Lawsuit #Gross_Law #Kyverna

Investors Alert: Upcoming Deadline for Kyverna Therapeutics Class Action Lawsuit A reminder to Kyverna Therapeutics investors regarding the upcoming deadline for a class action lawsuit connected to their IPO. Legal representation details included.

Investors Alert: Upcoming Deadline for Kyverna Therapeutics Class Action Lawsuit #USA #Kessler_Topaz #Radnor,_PA #Securities_Fraud #Kyverna

Investors in Kyverna Therapeutics Face Lawsuit Opportunity Amid IPO Misrepresentation Kyverna Therapeutics investors are urged to act by February 7, 2025, regarding a class action lawsuit linked to misleading IPO disclosures.

Investors in Kyverna Therapeutics Face Lawsuit Opportunity Amid IPO Misrepresentation #United_States #New_York #Rosen_Law_Firm #securities_lawsuit #Kyverna

Kyverna Therapeutics Announces Naji Gehchan as New Chief Medical Officer to Fuel Growth Kyverna Therapeutics has appointed Dr. Naji Gehchan, a veteran in clinical development, as Chief Medical and Development Officer to spearhead innovative therapies.

Kyverna Therapeutics Announces Naji Gehchan as New Chief Medical Officer to Fuel Growth #United_States #Emeryville #Cell_Therapy #Kyverna #Naji_Gehchan

Kyverna Therapeutics Faces Class Action as Investors Seek Justice for Securities Fraud Kyverna Therapeutics is embroiled in a class action lawsuit for alleged securities fraud tied to its IPO, prompting investors to take action. The deadline for lead plaintiffs is February 7, 2025.

Kyverna Therapeutics Faces Class Action as Investors Seek Justice for Securities Fraud #USA #Kessler_Topaz #Securities_Fraud #Radnor #Kyverna